Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(1):5-9
DOI: 10.5428/pcar20190102
Development of the standards for specific prescription review of proton pump inhibitor and clinical improvement
1. XI Wenli1(1.Department of Pharmacy,Kaifeng Central Hospital,He’nan Kaifeng 475000,China xiwenli1984@126.com)
2. JIANG Wei2(2.Department of Neurology,Kaifeng Central Hospital,He’nan Kaifeng 475000,China )
3. XIE Yun1(1.Department of Pharmacy,Kaifeng Central Hospital,He’nan Kaifeng 475000,China )
ABSTRACT  Objective: To perform specific prescription review of proton pump inhibitor (PPI),so as to improve rational use of drugs clinically and provide solid evidence for standardized application of PPI.Methods: The standards for specific prescription review of PPI were developed through the approaches of the organization of specific prescription review team and information retrieval of related guidelines.Three hundred medical history records were randomly selected respectively from those patients with PPI who were hospitalized in Kaifeng Central Hospital from July to September 2016 and during the same time span of 2017,and then,the rationality of PPI was evaluated and analyzed systemically.Results:Of the 300 medical records selected from the records kept during the period of July to September 2016,there were 132 medical records with irrational medication (with an irrationality rate of 44%).The main problems involved included medication without indications (29.1%),irrational selection of dosage (16.5%) and irrational application and dosage (15.8%).Feedback of the review results was duly made to related administrative and clinical physicians.Through repeated communication and clinical propaganda,irrational medication of PPI was effectively brought under control.Specific prescription review made from July to September 2017 indicated that the number of irrational medication dropped to 36,with a sharp decrease of irrationality (a rate of only 12%).Conclusion:Through the development of the standards for specific prescription review of PPI,irrational application of such drugs as PPI could be effectively avoided and safe medication could be greatly assured for patients.
Welcome to PCAR! You are the number 211 reader of this article!
Please cite this article as:
XI Wenli1,JIANG Wei2,XIE Yun1,. Development of the standards for specific prescription review of proton pump inhibitor and clinical improvement[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(1): 5-9.
References:
1. WU Junbiao,NI Xiaojia,CHEN She,et al.Summary and analysis of clinical practice guidelines for proton pump inhibitors in China[J].Chin Pharm J,2017,52(18):1649-1654.In Chinese with English abstract.
2. LEI Zhaobao.Adverse reactions and rational use of proton pump inhibitors[J].World Chin J Digestol,2016,24(23): 3468-3475.In Chinese with English abstract.
3. TAN Yunduxi,CAI Jia,FENG Wanyu.Utilization of proton pump inhibitors in six cities in China[J].Chin Pharm J,2015,50(9):821-823.In Chinese with English abstract.
4. Shin J M,Kim N.Pharmacokinetics and pharmacodynamics of the proton pump inhibitor[J].J Neurogastroenterol Motil,2013,19(1):25-35.
5. Gilard M,Arnaud B,Cornily J C, et al.Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized,double-blind OCLA (omeprazole clopidogrel aspirin) study[J].J Am Coll Cardiol,2008,51(3):256-260.
6. YOU Jiafei,DING Xuelan.Preoperative use of proton pump inhibitors in our hospital: analysis of 209 cases[J].Eval Anal Drug-Use Hosp China,2015,15(3):326-329.In Chinese with English abstract.
7. HU Jianwu,SU Yanwei,DU Lifen, et al.Investigation and analysis of prophylactic application of PPIs in AECOPD patients after glucocorticoid use in a hospital[J].China Pharmacy,2017,28(2):161-164.In Chinese with English abstract.
8. WU Lifang,ZHUO Shuangta,LIN Tao,et al. Pharmaceutical intervention of proton pump inhibitors on the prevention of the risk of digestive tract lesion caused by antithrombotic drugs[J].China Pharmacy,2015,26(8):1139-1141.In Chinese with English abstract.
9. Durand C,Willett K C and Desilets A R.Proton pump inhibitor use in hospitalized patients: is overutilization becoming a problem?[J].Clin Med Insights: Gastroenterol,2012,5: 65-76.
10. LI XueQing,Andersson T B,Ahlstrm M,et al.Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole,esomeprazole,lansoprazole,pantoprazole,and rabeprazole on human cytochrome P450 activities[J].Drug Metab Dispos,2004,32(8):821-827.
11. Daley R J,Rebuck J A,Welage L S, et al.Prevention of stress ulceration: current trends in critical care[J].Crit Care Med,2004,32(10):2008-2013.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口